β
1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase- producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66.
2. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases:
a clinical update. Clin Microbiol Rev 2005;18:657-86.
3. Pfaller MA, Espinel-Ingroff A, Boyken L, Hollis RJ, Kroeger J, Messer SA, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011;49:845-50.
4. Lee NY, Kim MS, Kim MN, Kim MJ, Kim SJ, Kim SI, et al.
Annual report on external quality assessment in clinical microbiology laboratory in Korea (2009). J Lab Med Qual Assur
2010;32:11-24. ( , , , , ,
, . (2009).
2010:32:11-24.)
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Wayne:
Clinical and Laboratory Standards Institute, 2009
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Wayne:
Clinical and Laboratory Standards Institute, 2010.
7. European Committee on Antimicrobial Susceptibility Testing, ed.
Breakpoint tables for interpretation of MICs and zone diameters.
Version 1.3. Vaxjo: EUCAST, 2011.
8. Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Domenech-Sanchez A, Swenson JM, et al. Characterization of the extended-spectrum beta-lactamase reference strain,Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 2000;44:
2382-8.
9. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M.
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum beta-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2012;67:159-66.
10. Rodriguez-Bano J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A; the ESBL-REIPI Group. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2011 Sep 13. [Epub ahead of print].
11. Song W, Park MJ, Kim HS, Kim JS, Kim HS, Lee KM.
Comparison of Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing breakpoints for beta-lactams in Enterobacteriaceae producing extended-spectrum beta-lactamases and/or plasmid-mediated
AmpC beta-lacta. Korean J Clin Microbiol 2011;14:24-9.
12. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
13. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics- pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47:1643-6.
14. Elkhaili H, Kamili N, Linger L, Leveque D, Pompei D, Monteil H, et al. In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta- lactamase. Chemotherapy 1997;43:245-53.
15. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia colion cefepime effectiveness. J Infect 2005;51:211-7.
16. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin
treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases:
implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
17. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7.
18. Arya SC, Agarwal N, Solanki BS, Agarwal S. Use of cefepime for the treatment of infections caused by extended spectrum:
beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Singapore Med J 2007;48:600-1.
19. Labombardi VJ, Rojtman A, Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006;56:313-5.
20. Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006;12:56-62.
